Academic Journals Database
Disseminating quality controlled scientific knowledge

Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems

ADD TO MY LIST
 
Author(s): Gabriele Capurso | Volker Fendrich | Maria Rinzivillo | Francesco Panzuto | Detlef K. Bartsch | Gianfranco Delle Fave

Journal: International Journal of Molecular Sciences
ISSN 1422-0067

Volume: 14;
Issue: 1;
Start page: 30;
Date: 2012;
Original page

Keywords: gastroenteropancreatic endocrine tumors | target therapy | mTOR | angiogenesis | Src | hedgehog | combined treatment | resistance

ABSTRACT
As more knowledge on molecular alterations favoring carcinogenesis and spreading of gastroenteropancreatic endocrine tumors has become available, a number of targeted agents interfering with key growth and angiogenic pathways have been explored in preclinical and clinical studies. The mTOR inhibitor Everolimus, and the multi-target antiangiogenetic agent Sunitinib, have been shown to be effective and thus have been approved by the FDA for treatment of pancreatic endocrine tumors. However, there is little data on the primary resistance to targeted agents on these tumors. The goals of the present review are to elucidate the possible advantage of combined treatments in overcoming induced resistances, and to identify biomarkers able to predict clinical efficacy. Moreover, the role of interesting targets for which a strong biological rationale exists, and specific inhibitors are available, such as the Src Family Kinases and the Hedgehog Pathway, are discussed. There is now need for more preclinical studies on cell lines and animal models to provide a stronger preclinical background in this field, as well as clinical trials specifically comparing one targeted therapy with another or combining different targeted agents.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions